Clinical Trial Update: Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) [Phase 3]

View source ↗

Summary

Open-label extension study update for seralutinib in adults with pulmonary arterial hypertension (PAH) continuing from a Phase 3 program.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Seralutinib (Seralutinib)

Snippet

Sponsor: GB002, Inc. | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: ACTIVE_NOT_RECRUITING